Sanofi India Limited Asset Resilience Ratio
Sanofi India Limited asset resilience ratio. Sanofi India Limited (SANOFI) has an Asset Resilience Ratio of 1.07% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Sanofi India Limited to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Sanofi India Limited (2010–2025)
Asset resilience ratio of Sanofi India Limited from 2010 to 2025. This chart shows how Sanofi India Limited's Asset Resilience Ratio has changed over time. Read Sanofi India Limited (SANOFI) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Sanofi India Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see SANOFI current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs150.00 Million | 1.07% |
| Total Liquid Assets | Rs150.00 Million | 1.07% |
Asset Resilience Insights
- Limited Liquidity: Sanofi India Limited maintains only 1.07% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Sanofi India Limited Industry Peers by Asset Resilience Ratio
Compare Sanofi India Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Merck & Company Inc
NYSE:MRK |
Drug Manufacturers - General | 0.22% |
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 0.10% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.33% |
|
Cosmo Pharmaceuticals N.V
F:C43 |
Drug Manufacturers - General | 10.92% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3 |
Drug Manufacturers - General | 6.34% |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436 |
Drug Manufacturers - General | 17.40% |
Sanofi India Limited Asset Resilience Ratio by Year (2010–2025)
Sanofi India Limited asset resilience ratio by year from 2010 to 2025. The table below shows the annual Asset Resilience Ratio data for Sanofi India Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 19.53% | Rs2.45 Billion ≈ $26.50 Million |
Rs12.55 Billion ≈ $135.70 Million |
+0.93pp |
| 2024-12-31 | 18.59% | Rs3.00 Billion ≈ $32.41 Million |
Rs16.12 Billion ≈ $174.31 Million |
-0.98pp |
| 2023-12-31 | 19.57% | Rs3.36 Billion ≈ $36.29 Million |
Rs17.15 Billion ≈ $185.45 Million |
-28.03pp |
| 2022-12-31 | 47.60% | Rs9.86 Billion ≈ $106.64 Million |
Rs20.72 Billion ≈ $224.05 Million |
+47.20pp |
| 2021-12-31 | 0.40% | Rs123.00 Million ≈ $1.33 Million |
Rs30.61 Billion ≈ $331.04 Million |
-0.56pp |
| 2020-12-31 | 0.96% | Rs281.00 Million ≈ $3.04 Million |
Rs29.18 Billion ≈ $315.62 Million |
-31.50pp |
| 2019-12-31 | 32.46% | Rs10.53 Billion ≈ $113.89 Million |
Rs32.44 Billion ≈ $350.87 Million |
+4.58pp |
| 2018-12-31 | 27.88% | Rs8.32 Billion ≈ $89.97 Million |
Rs29.84 Billion ≈ $322.70 Million |
+17.02pp |
| 2017-12-31 | 10.86% | Rs3.02 Billion ≈ $32.62 Million |
Rs27.77 Billion ≈ $300.32 Million |
-9.11pp |
| 2016-12-31 | 19.97% | Rs5.07 Billion ≈ $54.85 Million |
Rs25.40 Billion ≈ $274.69 Million |
+27.18pp |
| 2015-12-31 | -7.21% | Rs-1.73 Billion ≈ $-18.75 Million |
Rs24.05 Billion ≈ $260.05 Million |
-18.33pp |
| 2011-12-31 | 11.12% | Rs1.67 Billion ≈ $18.07 Million |
Rs15.03 Billion ≈ $162.50 Million |
-7.11pp |
| 2010-12-31 | 18.23% | Rs2.57 Billion ≈ $27.77 Million |
Rs14.08 Billion ≈ $152.31 Million |
-- |
About Sanofi India Limited
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company offers pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, anti-infectives, and central nervous system under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targoci… Read more